all report title image

TOURETTE SYNDROME TREATMENT MARKET ANALYSIS

Tourette Syndrome Treatment Market, by Drug Class (Antiadrenergic Agents, Antipsychotic Agents, Atypical Antipsychotics, Carbonic Anhydrase Inhibitor Anticonvulsants, Others), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Size, Share, Outlook, and Opportunity Analysis, 2022-2028

  • To Be Published : Nov 2024
  • Code : CMI2642
  • Formats :
      Excel and PDF
  • Industry : Pharmaceutical

Tourette syndrome is a rare and severe neurological disorder which causes tics. Tic is a repetitive involuntary movements, sudden, no rhythmic motor movements. It occurs due to the mutations of the SLITRK1 gene, which plays an important role in development of nerve cells. This syndrome usually occurs among the people of age between 2-15 years. There are four types of tics: motor tics (uncontrolled body movements), vocal tics (outburst of sound), simple tics (includes few parts of body) and complex tics (contains several parts of body). Tourette’s syndrome is related to other additional neurobehavioral problems like impulsivity, problems with reading and writing, obsessive compulsive symptoms. It can be treated with neuroleptics; haloperidol and pimozide are largely used medicines for Tourette syndrome. Other medications such as guanfacine and clonidine are useful to treat the severity of tics.

Tourette Syndrome Treatment Market Drivers

Drug approvals by regulatory authorities is expected to boost the global tourette syndrome treatment market growth. For instance, in October 23, 2017, Neurocrine Biosciences Inc. announced that the Food Drug and Administration approved valbenazine orphan drug designation to treat the pediatric patients with the Tourette syndrome. Furthermore, in September 19, 2017, Teva Pharmaceutical Industries and Nuvelution Pharma announced their partnership to develop AUSTEDO (deutetrabenazine) tablets for the treatment of tics which is associated to tourette syndrome in pediatric patients in the U.S. This partnership will drive the development of Austedo (deutetrabenazine) in Tourette syndrome by bringing new treatment options more quickly which are more necessary for the affected young patients. These factors are expected to propel the global Tourette syndrome treatment market growth.

Moreover, there are several investigations made for the treatment of Tourette syndrome. For instance, in March 2019, Wesley Medical Research was partnering with the University of Sydney in Australia which carried the clinical trial to investigate whether the medical cannabis could be used to treat the individuals with Tourette syndrome. This trial will help examine efficacy and safety of cannabinoids on tic frequency as well as the psychiatric symptoms associated with Tourette syndrome.

Furthermore, the acquisitions of companies drive the growth of the Tourette syndrome treatment market. For instance, on August 14, 2018, Emalex Biosciences acquired the Psyadon Pharmaceuticals and the rights to develop, register and market ecopipam, the investigational drug of Psyadon Pharmaceuticals, which is used to treat the Tourette syndrome in children less than 16 years of age.

Tourette Syndrome Treatment Market Regional Analysis

On the basis of region, the Tourette syndrome market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. North America is expected to hold a dominant position in the Tourette syndrome treatment market due to presence of large number of key players like Otsuka Holdings Co., Ltd, AstraZeneca PLC, Catalyst Pharmaceutical Parteners, Inc. In terms of revenue, U.S. contributes the major share of this syndrome treatment market. According to the National Institute Of Neurological Disorders And Stroke(NIH), it is estimated that around 2,00,000 Americans have the most severe form of Tourette syndrome and as many as one in 100 shows milder or less complex symptoms such as vocal tics.

Tourette Syndrome Treatment Market Restraints

Withdrawal of the drugs in late stages of clinical trials has hampered the global Tourette syndrome treatment market growth. For instance, on December 12, 2018, Neurocrine Biosciences revealed that the phase IIb study of valbenazine did not meet the primary endpoint of reducing the tic severity in young people in moderate to severe form of diseases.

Tourette Syndrome Treatment Market Key Players

Some of the major players operating in the global Tourette syndrome treatment market include Neurocrine Biosciences Inc., Novartis AG, Otsuka Pharmaceutical Co., Ltd., Apotex, Inc., Janssen Pharmaceuticals, Inc., Teva Pharmaceuticals, Zydus Pharmaceuticals, Torrent Pharmaceuticals Limited and Eli Lilly Pharmaceuticals.

Tourette syndrome treatment Market Taxonomy

On the basis of drug class, the global Tourette syndrome treatment market is segmented into:

  • Antiadrenergic Agents
  • Antipsychotic Agents
  • Atypical Antipsychotics
  • Carbonic Anhydrase Inhibitor Anticonvulsants
  • Others

On the basis of distribution channel, the global Tourette syndrome treatment market is segmented into:

  • Hospital pharmacies
  • Retail pharmacies
  • Online pharmacies

On the basis of region, the global Tourette syndrome treatment market is segmented into:

  • North America
  • Latin America
  • Europe
  • Asia Pacific
  • Middle East
  • Africa

Share

About Author

Vipul Patil

Vipul Patil is a dynamic management consultant with 6 years of dedicated experience in the pharmaceutical industry. Known for his analytical acumen and strategic insight, Vipul has successfully partnered with pharmaceutical companies to enhance operational efficiency, cross broader expansion, and navigate the complexities of distribution in markets with high revenue potential.

Missing comfort of reading report in your local language? Find your preferred language :

Logo

Credibility and Certifications

ESOMAR
DUNS Registered

860519526

Clutch
Credibility and Certification
Credibility and Certification

9001:2015

Credibility and Certification

27001:2022

Logo

Credibility and Certifications

ESOMAR
DUNS Registered

860519526

Clutch
Credibility and Certification
Credibility and Certification

9001:2015

Credibility and Certification

27001:2022

Need a Custom Report?

We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports

Customize Now

Select a License Type





Logo

Credibility and Certifications

ESOMAR
DUNS Registered

860519526

Clutch
Credibility and Certification
Credibility and Certification

9001:2015

Credibility and Certification

27001:2022

EXISTING CLIENTELE

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients
trusted clients logo
© 2024 Coherent Market Insights Pvt Ltd. All Rights Reserved.